Alpha 2.0
Login Register
» Articles » PMID: 30855999

Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation

Overview
Journal Circulation
Specialty Cardiology & Vascular Diseases
Date 2019 Mar 12
PMID 30855999
Citations 8
Authors
Wilfried Mullens
Pieter Martens
Affiliations
Soon will be listed here.
Citing Articles

COAPT Trial at 5 Years: Same Doubts Remain About the Efficacy of Transcatheter Edge-to-Edge in Functional Mitral Regurgitation.

Garcia-Villarreal O, Chunming D Braz J Cardiovasc Surg. 2024; 39(4):e20230360.

PMID: 39418233 PMC: 11484088. DOI: 10.21470/1678-9741-2023-0360.

Insight from International Guidelines: do We Have Satisfactory Recommendations for Secondary Mitral Regurgitation?.

Nappi F, Avtaar Singh S, Fiore A, Ellouze O Rev Cardiovasc Med. 2024; 23(5):180.

PMID: 39077618 PMC: 11273860. DOI: 10.31083/j.rcm2305180.

Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure.

Kodsi M, Makarious D, Gan G, Choudhary P, Thomas L ESC Heart Fail. 2023; 10(6):3258-3275.

PMID: 37871982 PMC: 10682888. DOI: 10.1002/ehf2.14555.

Plausible Functional Diagnostics by Rational Echocardiography in the Assessment of Valvular Heart Disease - Role of Quantitative Echocardiography in the Assessment of Mitral Regurgitation.

Hagendorff A, Stobe S Front Cardiovasc Med. 2022; 9:819915.

PMID: 35433886 PMC: 9008256. DOI: 10.3389/fcvm.2022.819915.

Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.

Abumayyaleh M, Demmer J, Krack C, Pilsinger C, El-Battrawy I, Behnes M Am J Cardiovasc Drugs. 2022; 22(5):535-544.

PMID: 35353351 PMC: 9468101. DOI: 10.1007/s40256-022-00525-w.